CN109007838A - A kind of functional health care food and preparation method thereof of lecithin norcholesterol - Google Patents
A kind of functional health care food and preparation method thereof of lecithin norcholesterol Download PDFInfo
- Publication number
- CN109007838A CN109007838A CN201810825155.7A CN201810825155A CN109007838A CN 109007838 A CN109007838 A CN 109007838A CN 201810825155 A CN201810825155 A CN 201810825155A CN 109007838 A CN109007838 A CN 109007838A
- Authority
- CN
- China
- Prior art keywords
- lecithin
- norcholesterol
- functional health
- poly
- health care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 58
- 230000036541 health Effects 0.000 title claims abstract description 54
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 title claims abstract description 47
- 229940067606 lecithin Drugs 0.000 title claims abstract description 47
- 239000000787 lecithin Substances 0.000 title claims abstract description 47
- 235000010445 lecithin Nutrition 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims abstract description 64
- 108010064470 polyaspartate Proteins 0.000 claims abstract description 60
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 54
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 49
- 239000003240 coconut oil Substances 0.000 claims abstract description 49
- 229960002666 1-octacosanol Drugs 0.000 claims abstract description 32
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 19
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 19
- 238000004090 dissolution Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 235000015067 sauces Nutrition 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 14
- 239000003208 petroleum Substances 0.000 claims description 11
- 241000238557 Decapoda Species 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 241000239370 Euphausia superba Species 0.000 claims description 8
- 235000013402 health food Nutrition 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 claims description 6
- 241000432824 Asparagus densiflorus Species 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- ZYURHZPYMFLWSH-UHFFFAOYSA-N octacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC ZYURHZPYMFLWSH-UHFFFAOYSA-N 0.000 claims 4
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 15
- 230000002787 reinforcement Effects 0.000 abstract description 7
- 235000012041 food component Nutrition 0.000 abstract 1
- 239000005417 food ingredient Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 210000004204 blood vessel Anatomy 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 210000000232 gallbladder Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 150000002978 peroxides Chemical class 0.000 description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000017448 oviposition Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000005053 encephalomalacia Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of functional health care foods and preparation method thereof of lecithin norcholesterol, belong to health product technology field.The functional health care food ingredient of the lecithin norcholesterol includes soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil；The functional health care food of the lecithin norcholesterol is dissolution, is concentrated, and drying and other steps are made.The present invention is reinforcement system by using poly-aspartate, long chain triglycerides, coconut oil, improves therapeutic effect, is reduced to body burden.
Description
Technical field
The invention belongs to health product technology fields, and in particular to a kind of functional health care food of lecithin norcholesterol and its
Preparation method.
Background technique
Hyperlipidemia is common clinical and frequently-occurring disease, and there are about 1.6 hundred million people to suffer from dyslipidemia in China at present, and adult blood lipid is different
Normal total prevalence rate is 18.6%.Dyslipidemia is the important risk factor of myocardial infarction and cerebral thrombosis, seriously endangers China town and country
The health of resident.There are about 40% in the annual death toll in China to die of cardiovascular disease, and the data that the Ministry of Public Health in 2005 announces is aobvious
Show: there are about 3,000,000 people to die of cardiovascular disease every year in the whole nation, and about 8000 people, is roughly equal to every 10 seconds 1 people daily.Newly make up one's mind every year
Flesh infarct and cerebral thrombus patient's number are respectively 500,000 and 2,000,000.China's cardiovascular disease is with ischemic (including coronary heart disease and brain blood
Bolt) based on, the pathologic basis of ischemic cardiovascular disease (including coronary heart disease and cerebral thrombosis) is atherosclerosis.Cause artery congee
The risk factor of sample hardening includes high cholesterol, hypertension, diabetes, smoking etc., and especially previous high gallbladder not enough of paying attention to is consolidated
Alcohol.Cholesterol includes that low density lipoprotein cholesterol (being commonly called as " bad " cholesterol) and high-density lipoprotein cholesterol (are commonly called as " good "
Cholesterol).Low density lipoprotein cholesterol increases harm maximum, is the primary condition for leading to atherosclerosis.Low density lipoprotein
Protein cholesterol can form atherosclerotic plaque in blood vessel.Patch constantly increases, and keeps artery gradually narrow or even blocks,
Cause angina pectoris, myocardial ischemia, cerebral infarction, cerebromalacia.These patches, can be in no any tendency just as " not timing bomb "
In the case of rupture, block blood vessel rapidly, cause acute myocardial infarction AMI and even die suddenly.It is a large amount of clinical since the 1960s
Studies have shown that cholesterol is every to reduce by 1%, the incidence of coronary heart disease will reduce by 2%, referred to as 1=2 formula.Currently, blood lipid is different
Normal primary therapeutic purpose is to reduce low density lipoprotein cholesterol.Reasonable diet and rule movement are not only prevention dyslipidemia
Fundamental means, and be treat dyslipidemia basis.The treatment of hyperlipidemia should be set about first from diet, i.e., low fat,
Low sugar, high-protein diet, fasting animals internal organ such as liver, kidney, the heart, brain etc. will also lose weight and control weight.Not to dietary therapy reaction
Obviously, drug therapy can be carried out.Health ministry recommends lipid-lowering statins within 2008: statins can significantly reduce low
Density lipoprotein-cholesterol, while also reducing triglycerides and slight increasing high density lipoprotein cholesterol；In addition, Statins is also
There may be anti-inflammatory, protection function of vascular endothelium.Nearly 20 years clinical studies shows, statins are to reduce gallbladder to consolidate
Alcohol prevents myocardial infarction and the most effective drug of cerebral thrombosis.However be medicine " three points of poison ", in general, lipid-lowering medicine has secondary work
, long-term administration will lead to the damage of liver and kidney.Therefore selecting lipid-lowering medicine to carry out the treatment of hyperlipidemia is that many patients are difficult to
It faces.It is not resistant to the hypercholesterolemiapatients patients of statins especially.Because the invention one kind is specifically for hyperlipidemia
The dual-purpose of drug and food based food of crowd is with regard to particularly necessary.
Chinese patent literature " a kind of functional health-care food of norcholesterol (patent No.: CN102309004B) " discloses
A kind of functional health-care food of norcholesterol, it is characterised in that: its composition is made of soybean lecithin and n-octacosanol, institute
State parts by weight contained by two compositions are as follows: soybean lecithin 99%-99.8%, n-octacosanol 0.2%-1%.The invention has
Beneficial effect is: while having the function of effective norcholesterol, also having the function of weight-reducing, establishing-Yang, but its effect is also
It is overweight to body burden wait improve.
Summary of the invention
The object of the present invention is to provide a kind of functional health care foods and preparation method thereof of lecithin norcholesterol, to solve
The norcholesterol disclosed in patent document " a kind of functional health-care food of norcholesterol (patent No.: CN102309004B) "
On the basis of functional health-care food, optimize component, dosage, method of functional health care food etc., improves lecithin norcholesterol
Functional health care food therapeutic effect, reduce to body burden.
In order to solve the above technical problems, the invention adopts the following technical scheme:
A kind of functional health care food of lecithin norcholesterol, ingredient include soybean lecithin, n-octacosanol, poly- day
Aspartic acid, long chain triglycerides, coconut oil；The poly-aspartate, long chain triglycerides, the weight ratio of coconut oil are (4-8):
(1-3): (3-7).
Further, the poly-aspartate, long chain triglycerides, the weight ratio of coconut oil are 6:2:5.
Further, the functional health care food is as unit of parts by weight, including following raw material: soybean lecithin 95-98
Mass parts, n-octacosanol 2-4 mass parts, poly-aspartate 4-8 mass parts, long chain triglycerides 1-3 mass parts, coconut oil 3-
7 mass parts.
Further, the functional health care food is as unit of parts by weight, including following raw material: 96.5 matter of soybean lecithin
Measure part, 3 mass parts of n-octacosanol, 6 mass parts of poly-aspartate, 2 mass parts of long chain triglycerides, 5 mass parts of coconut oil.
Further, the n-octacosanol is the monohydric alcohol extracted from euphausia superba sauce.
Further, the n-octacosanol by NaOH ethanol solution by being heated to reflux euphausia superba sauce, stone
After oily ether extracts and be evaporated off petroleum ether processing shrimp sauce, n-octacosanol is obtained.
Further, the molecular weight 1500-3000 of the poly-aspartate.
A kind of preparation method of the functional health care food of above-mentioned lecithin norcholesterol, comprising the following steps:
(1) soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil are added to ethanol solution
In, Microwave Dissolution；(2) at sticky mass after being concentrated；(3) by after sticky mass drying, 80 meshes are crossed.
The invention has the following advantages:
(1) as the data of embodiment 1-3 and comparative example 5 as it can be seen that the function of lecithin norcholesterol made from embodiment 1-3
The therapeutic effect and reduction body burden significant effect of health food are higher than the function of lecithin norcholesterol made from comparative example 5
The therapeutic effect and reduction body burden effect of health food；Simultaneously by the data of embodiment 1-3 as it can be seen that embodiment 1 is optimal
Embodiment.
(2) by embodiment 1 and the data of comparative example 1-4 as it can be seen that poly-aspartate, long chain triglycerides, coconut oil are in life
Synergistic effect is played in the functional health care food of oviposition phosphatide norcholesterol, collaboration improves the function of lecithin norcholesterol
The therapeutic effect and reduction body burden effect of health food；
After lecithin is absorbed into blood circulation, serum lipids can be improved, remove peroxide, make Blood Cholesterol and
Neutral fat content reduces, and reduces the residence time of fatty wall in the blood vessels, promotes the dissipation of atherosis spot, prevent from being consolidated by gallbladder
Blood vessel internal membrane damage caused by alcohol.Taking lecithin has significant effect to hyperlipidemia and high cholesterol, thus can prevent and
Treat artery sclerosis.Octadecanol may inhibit the accumulation of lipid in the tissue, and in epididymis greasiness matter tissue and liver
Fat content is without influence.Supplement n-octacosanol can also reduce the content of triglycerides in blood plasma, improve the content of fatty acid.
Poly-aspartate is a kind of polymeric amino acid with carboxylic acid side chain, has chelating to peroxide and goes back original work
With poly-aspartate can make long chain triglycerides arrive poly-aspartate by Hydrogenbond because of the peptide bond on its structural backbone
On strand, it can be enriched with the effect of grease using long chain triglycerides, improve the oil absorbing effect of poly-aspartate, and more hold
Easily take external, raising therapeutic effect out of；Long chain triglycerides can promote poly-aspartate to absorb, with general intracorporal glycerol
Three esters are different, backbone can its in the retention period be adsorbed onto blood vessel, reduce other greases and accumulated on vascular wall,
Increase poly-aspartate residence time in vivo, improve curative effect and reduce the burden of human body, while it can promote sticky coconut
Oily emulsion dispersion improves curative effect to promote coconut oil by stomach absorption efficiency；The oil that coconut oil is made of medium chain fatty acid
The long-chain fat molecule of rouge, other foods of Medium chain fatty molecular proportion is small, easily digested, the digestion nothing of dietotherapy coconut oil
Human body pancreas digestive ferment system need to be employed, the enzyme and hormonal system to body apply the pressure of very little, and its surface is abundant
Polar group, can be compound with poly-aspartate and long chain triglycerides progress, so that the system dispersion for forming three is more evenly
And stabilization, it is easier to be absorbed by the body, improve curative effect, coconut oil can reduce poly- asparagus fern ammonia due to its mild natural characteristic
Acid and long chain triglycerides metabolic burden caused by human body, promote it smoothly to exclude in vitro.
(3) by the data of comparative example 6-8 as it can be seen that poly-aspartate, long chain triglycerides, the weight ratio of coconut oil do not exist
(4-8): (1-3): when in (3-7) range, the therapeutic effect and reduction of the functional health care food of lecithin norcholesterol obtained
Human body burden effect and the numerical value of embodiment 1-3 are very different, much smaller than the numerical value of embodiment 1-3, with the prior art (comparative example
5) numerical value is suitable.Poly-aspartate of the present invention, long chain triglycerides, coconut oil are as reinforcement system, embodiment 1-3 control life
By adding poly-aspartate, long chain triglycerides, the weight of coconut oil when the functional health care food of oviposition phosphatide norcholesterol
Than for (4-8): (1-3): (3-7) is realized and is utilized grease and reduction peroxide in poly-aspartate enrichment blood vessel in reinforcement system
Compound；Long chain triglycerides promote poly-aspartate to absorb, and increase poly-aspartate residence time in vivo；Coconut oil can with it is poly-
Aspartic acid and long chain triglycerides progress are compound, to keep the two more evenly and stable in dispersion, it is easier to it is absorbed by the body,
Curative effect is improved, the mild characteristic of coconut oil can reduce human body burden, so that poly-aspartate, long chain triglycerides, coconut oil
It is solid to improve lecithin drop gallbladder in the preparation of the functional health care food of lecithin norcholesterol of the invention for the reinforcement system of composition
The therapeutic effect and reduction human body burden of the functional health care food of alcohol.
Specific embodiment
To facilitate a better understanding of the present invention, it is illustrated by the following examples, these examples belong to protection of the invention
Range, but do not limit the scope of the invention.
In embodiment, a kind of functional health care food of lecithin norcholesterol, as unit of parts by weight, including following original
Material: soybean lecithin 95-98 mass parts, n-octacosanol 2-4 mass parts, poly-aspartate 4-8 mass parts, long chain triglycerides
1-3 mass parts, coconut oil 3-7 mass parts.
The n-octacosanol is the monohydric alcohol extracted from euphausia superba sauce.The n-octacosanol is by by the South Pole
Krill shrimp sauce, be heated to reflux by NaOH ethanol solution, petroleum ether extraction and be evaporated off petroleum ether processing shrimp sauce after, obtain 28
Alkanol.The molecular weight 1500-3000 of the poly-aspartate.
A kind of preparation method of the functional health care food of above-mentioned lecithin norcholesterol, comprising the following steps:
(1) soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil are added to ethanol solution
In, Microwave Dissolution；(2) at sticky mass after being concentrated；(3) by after sticky mass drying, 80 meshes are crossed.
Embodiment 1
A kind of functional health care food of lecithin norcholesterol, as unit of parts by weight, including following raw material: soybean lecithin
96.5 mass parts of rouge, 3 mass parts of n-octacosanol, 6 mass parts of poly-aspartate, 2 mass parts of long chain triglycerides, coconut oil 5
Mass parts.
The n-octacosanol is the monohydric alcohol extracted from euphausia superba sauce.The n-octacosanol is by by the South Pole
Krill shrimp sauce, be heated to reflux by NaOH ethanol solution, petroleum ether extraction and be evaporated off petroleum ether processing shrimp sauce after, obtain 28
Alkanol.The molecular weight 2000 of the poly-aspartate.
A kind of preparation method of the functional health care food of above-mentioned lecithin norcholesterol, comprising the following steps:
(1) soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil are added to ethanol solution
In, Microwave Dissolution；(2) at sticky mass after being concentrated；(3) by after sticky mass drying, 80 meshes are crossed.
Embodiment 2
A kind of functional health care food of lecithin norcholesterol, as unit of parts by weight, including following raw material: soybean lecithin
98 mass parts of rouge, 2 mass parts of n-octacosanol, 8 mass parts of poly-aspartate, 1 mass parts of long chain triglycerides, 7 matter of coconut oil
Measure part.
The n-octacosanol is the monohydric alcohol extracted from euphausia superba sauce.The n-octacosanol is by by the South Pole
Krill shrimp sauce, be heated to reflux by NaOH ethanol solution, petroleum ether extraction and be evaporated off petroleum ether processing shrimp sauce after, obtain 28
Alkanol.The molecular weight 1500 of the poly-aspartate.
A kind of preparation method of the functional health care food of above-mentioned lecithin norcholesterol, comprising the following steps:
(1) soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil are added to ethanol solution
In, Microwave Dissolution；(2) at sticky mass after being concentrated；(3) by after sticky mass drying, 80 meshes are crossed.
Embodiment 3
A kind of functional health care food of lecithin norcholesterol, as unit of parts by weight, including following raw material: soybean lecithin
98 mass parts of rouge, 2 mass parts of n-octacosanol, 8 mass parts of poly-aspartate, 1 mass parts of long chain triglycerides, 7 matter of coconut oil
Measure part.
The n-octacosanol is the monohydric alcohol extracted from euphausia superba sauce.The n-octacosanol is by by the South Pole
Krill shrimp sauce, be heated to reflux by NaOH ethanol solution, petroleum ether extraction and be evaporated off petroleum ether processing shrimp sauce after, obtain 28
Alkanol.The molecular weight 3000 of the poly-aspartate.
A kind of preparation method of the functional health care food of above-mentioned lecithin norcholesterol, comprising the following steps:
(1) soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil are added to ethanol solution
In, Microwave Dissolution；(2) at sticky mass after being concentrated；(3) by after sticky mass drying, 80 meshes are crossed.
Comparative example 1
It is essentially identical with the production technology of embodiment 1, have only unlike prepare and lack in the raw material of functional health care food
Poly-aspartate, long chain triglycerides, coconut oil.
Comparative example 2
It is essentially identical with the production technology of embodiment 1, have only unlike prepare and lack in the raw material of functional health care food
Poly-aspartate.
Comparative example 3
It is essentially identical with the production technology of embodiment 1, have only unlike prepare and lack in the raw material of functional health care food
Long chain triglycerides.
Comparative example 4
It is essentially identical with the production technology of embodiment 1, have only unlike prepare and lack in the raw material of functional health care food
Coconut oil.
Comparative example 5
Using in Chinese patent literature " a kind of functional health-care food of norcholesterol (patent No.: CN102309004B) "
The functional health care food of the production lecithin norcholesterol of method described in specific embodiment 1.
Comparative example 6
It is essentially identical with the preparation process of embodiment 1, it has only the difference is that preparing the functional health of lecithin norcholesterol
Poly-aspartate is 2 parts in the raw material of food, long chain triglycerides are 5 parts, coconut oil is 2 parts.
Comparative example 7
It is essentially identical with the preparation process of embodiment 1, it has only the difference is that preparing the functional health of lecithin norcholesterol
Poly-aspartate is 10 parts in the raw material of food, long chain triglycerides are 0.5 part, coconut oil is 10 parts.
Comparative example 8
It is essentially identical with the preparation process of embodiment 1, it has only the difference is that preparing the functional health of lecithin norcholesterol
Poly-aspartate is 2 parts in the raw material of food, long chain triglycerides are 5 parts, coconut oil is 10 parts.
The functional health care food of lecithin norcholesterol, 10g agent are produced according to the technique of embodiment 1-3 and comparative example 1-8
Amount 10-12 week tests TG slippage, and by test assessment side effect grade 1-5,5 is without side-effects, and 1 is that side effect is obvious,
As a result as shown in the table.
| Experimental project | TG slippage | Side effect |
| Embodiment 1 | 25 | 5 |
| Embodiment 2 | 24 | 5 |
| Embodiment 3 | 23 | 5 |
| Comparative example 1 | 6 | 2 |
| Comparative example 2 | 22 | 3 |
| Comparative example 3 | 19 | 4 |
| Comparative example 4 | 20 | 4 |
| Comparative example 5 | 12 | 2 |
| Comparative example 6 | 14 | 3 |
| Comparative example 7 | 15 | 3 |
| Comparative example 8 | 16 | 3 |
As seen from the above table: (1) as the data of embodiment 1-3 and comparative example 5 as it can be seen that lecithin made from embodiment 1-3 drops
The therapeutic effect and reduction body burden significant effect of the functional health care food of cholesterol are higher than the drop of lecithin made from comparative example 5
The therapeutic effect and reduction body burden effect of the functional health care food of cholesterol；Simultaneously by the data of embodiment 1-3 as it can be seen that reality
Applying example 1 is optimum embodiment.
(2) by embodiment 1 and the data of comparative example 1-4 as it can be seen that poly-aspartate, long chain triglycerides, coconut oil are in life
Synergistic effect is played in the functional health care food of oviposition phosphatide norcholesterol, collaboration improves the function of lecithin norcholesterol
The therapeutic effect and reduction body burden effect of health food；This is:
After lecithin is absorbed into blood circulation, serum lipids can be improved, remove peroxide, make Blood Cholesterol and
Neutral fat content reduces, and reduces the residence time of fatty wall in the blood vessels, promotes the dissipation of atherosis spot, prevent from being consolidated by gallbladder
Blood vessel internal membrane damage caused by alcohol.Taking lecithin has significant effect to hyperlipidemia and high cholesterol, thus can prevent and
Treat artery sclerosis.Octadecanol may inhibit the accumulation of lipid in the tissue, and in epididymis greasiness matter tissue and liver
Fat content is without influence.Supplement n-octacosanol can also reduce the content of triglycerides in blood plasma, improve the content of fatty acid.
Poly-aspartate is a kind of polymeric amino acid with carboxylic acid side chain, has chelating to peroxide and goes back original work
With poly-aspartate can make long chain triglycerides arrive poly-aspartate by Hydrogenbond because of the peptide bond on its structural backbone
On strand, it can be enriched with the effect of grease using long chain triglycerides, improve the oil absorbing effect of poly-aspartate, and more hold
Easily take external, raising therapeutic effect out of；Long chain triglycerides can promote poly-aspartate to absorb, with general intracorporal glycerol
Three esters are different, backbone can its in the retention period be adsorbed onto blood vessel, reduce other greases and accumulated on vascular wall,
Increase poly-aspartate residence time in vivo, improve curative effect and reduce the burden of human body, while it can promote sticky coconut
Oily emulsion dispersion improves curative effect to promote coconut oil by stomach absorption efficiency；The oil that coconut oil is made of medium chain fatty acid
The long-chain fat molecule of rouge, other foods of Medium chain fatty molecular proportion is small, easily digested, the digestion nothing of dietotherapy coconut oil
Human body pancreas digestive ferment system need to be employed, the enzyme and hormonal system to body apply the pressure of very little, and its surface is abundant
Polar group, can be compound with poly-aspartate and long chain triglycerides progress, so that the system dispersion for forming three is more evenly
And stabilization, it is easier to be absorbed by the body, improve curative effect, coconut oil can reduce poly- asparagus fern ammonia due to its mild natural characteristic
Acid and long chain triglycerides metabolic burden caused by human body, promote it smoothly to exclude in vitro.
(3) by the data of comparative example 6-8 as it can be seen that poly-aspartate, long chain triglycerides, the weight ratio of coconut oil do not exist
(4-8): (1-3): when in (3-7) range, the therapeutic effect and reduction of the functional health care food of lecithin norcholesterol obtained
Human body burden effect and the numerical value of embodiment 1-3 are very different, much smaller than the numerical value of embodiment 1-3, with the prior art (comparative example
5) numerical value is suitable.Poly-aspartate of the present invention, long chain triglycerides, coconut oil are as reinforcement system, embodiment 1-3 control life
By adding poly-aspartate, long chain triglycerides, the weight of coconut oil when the functional health care food of oviposition phosphatide norcholesterol
Than for (4-8): (1-3): (3-7) is realized and is utilized grease and reduction peroxide in poly-aspartate enrichment blood vessel in reinforcement system
Compound；Long chain triglycerides promote poly-aspartate to absorb, and increase poly-aspartate residence time in vivo；Coconut oil can with it is poly-
Aspartic acid and long chain triglycerides progress are compound, to keep the two more evenly and stable in dispersion, it is easier to it is absorbed by the body,
Curative effect is improved, the mild characteristic of coconut oil can reduce human body burden, so that poly-aspartate, long chain triglycerides, coconut oil
It is solid to improve lecithin drop gallbladder in the preparation of the functional health care food of lecithin norcholesterol of the invention for the reinforcement system of composition
The therapeutic effect and reduction human body burden of the functional health care food of alcohol.
The above content is it cannot be assumed that present invention specific implementation is only limited to these instructions, for the technical field of the invention
Those of ordinary skill for, under the premise of not departing from present inventive concept, a number of simple deductions or replacements can also be made, all answers
When being considered as belonging to present invention scope of patent protection determined by the appended claims.
Claims (8)
1. a kind of functional health care food of lecithin norcholesterol, which is characterized in that its ingredient includes soybean lecithin, and 28
Alkanol, poly-aspartate, long chain triglycerides, coconut oil；The poly-aspartate, long chain triglycerides, the weight of coconut oil
Than for (4-8): (1-3): (3-7).
2. the functional health care food of lecithin norcholesterol according to claim 1, which is characterized in that the poly- asparagus fern ammonia
Acid, long chain triglycerides, the weight ratio of coconut oil are 6:2:5.
3. the functional health care food of lecithin norcholesterol according to claim 1, which is characterized in that the functional health
Food is as unit of parts by weight, including following raw material: soybean lecithin 95-98 mass parts, n-octacosanol 2-4 mass parts, gathers
Aspartic acid 4-8 mass parts, long chain triglycerides 1-3 mass parts, coconut oil 3-7 mass parts.
4. the functional health care food of lecithin norcholesterol according to claim 1, which is characterized in that the functional health
Food is as unit of parts by weight, including following raw material: 96.5 mass parts of soybean lecithin, 3 mass parts of n-octacosanol, poly- asparagus fern
6 mass parts of propylhomoserin, 2 mass parts of long chain triglycerides, 5 mass parts of coconut oil.
5. the functional health care food of lecithin norcholesterol according to claim 1, which is characterized in that the octacosane
Alcohol is the monohydric alcohol extracted from euphausia superba sauce.
6. the functional health care food of lecithin norcholesterol according to claim 1, which is characterized in that the octacosane
Alcohol by being heated to reflux by NaOH ethanol solution by euphausia superba sauce, petroleum ether extraction and be evaporated off petroleum ether processing shrimp sauce
Afterwards, n-octacosanol is obtained.
7. the functional health care food of lecithin norcholesterol according to claim 1, which is characterized in that the poly- asparagus fern ammonia
The molecular weight 1500-3000 of acid.
8. a kind of preparation method of the functional health care food of lecithin norcholesterol according to claim 1-7,
Characterized by comprising the following steps:
(1) soybean lecithin, n-octacosanol, poly-aspartate, long chain triglycerides, coconut oil are added in ethanol solution,
Microwave Dissolution；(2) at sticky mass after being concentrated；(3) by after sticky mass drying, 80 meshes are crossed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810825155.7A CN109007838A (en) | 2018-07-25 | 2018-07-25 | A kind of functional health care food and preparation method thereof of lecithin norcholesterol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810825155.7A CN109007838A (en) | 2018-07-25 | 2018-07-25 | A kind of functional health care food and preparation method thereof of lecithin norcholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109007838A true CN109007838A (en) | 2018-12-18 |
Family
ID=64645905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810825155.7A Withdrawn CN109007838A (en) | 2018-07-25 | 2018-07-25 | A kind of functional health care food and preparation method thereof of lecithin norcholesterol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109007838A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695377A (en) * | 2009-09-14 | 2010-04-21 | 蔡晓东 | Soya bean lecithin soft capsule |
| CN102309004A (en) * | 2011-09-23 | 2012-01-11 | 缪志轩 | Functional health food with lowering cholesterol |
| CN103439451A (en) * | 2013-08-16 | 2013-12-11 | 山东师范大学 | Extraction and thin-layer chromatographic scanning detection method for octacosanol from Antarctic krill |
| CN107712900A (en) * | 2017-10-24 | 2018-02-23 | 宝得瑞（湖北）健康产业有限公司 | Long-chain fat acid glyceride microcapsules and its production method in a kind of feature |
-
2018
- 2018-07-25 CN CN201810825155.7A patent/CN109007838A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695377A (en) * | 2009-09-14 | 2010-04-21 | 蔡晓东 | Soya bean lecithin soft capsule |
| CN102309004A (en) * | 2011-09-23 | 2012-01-11 | 缪志轩 | Functional health food with lowering cholesterol |
| CN103439451A (en) * | 2013-08-16 | 2013-12-11 | 山东师范大学 | Extraction and thin-layer chromatographic scanning detection method for octacosanol from Antarctic krill |
| CN107712900A (en) * | 2017-10-24 | 2018-02-23 | 宝得瑞（湖北）健康产业有限公司 | Long-chain fat acid glyceride microcapsules and its production method in a kind of feature |
Non-Patent Citations (2)
| Title |
|---|
| 王国建等: "《特种与功能高分子材料》", 31 October 2004, 中国石化出版社 * |
| 禤小凤等: "椰子油的生理活性(Ⅱ)：调节血浆血脂", 《热带农业科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5503846B2 (en) | Use of a fatty acid composition containing DHA in the manufacture of a medical or food product for the treatment of amyloidosis-related diseases | |
| AU2014292541B2 (en) | Alkaloid compositions from ribes species to treat conditions assosiated with mitochondrial function or inhibition of PDE4, PDE5 and IKK-Beta | |
| RO120950B1 (en) | Bioactive complex of triterpene acids, process of preparation, medicinal products with therapeutical applications | |
| RU2657757C2 (en) | Novel extracts of cynara scolymus, coffea spp. and olea europaea for the treatment of metabolic syndrome | |
| KR102087634B1 (en) | Composition for anti-obesity | |
| WO2013031729A1 (en) | Prophylactic/therapeutic agent for cardiovascular complications of diabetes | |
| FR3061658A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AS ACTIVE INGREDIENT A COMBINATION OF D-LIMONEME, LUPEOL AND CINNAMALDEHYDE AND / OR POLYMERIC METHYLHYDROXYCHALCONE AND / OR BETA-SITOSTEROL AND / OR | |
| Jacobson | Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease | |
| CN105232525A (en) | Hypolipidemic drug combination and application thereof | |
| JP2006347952A (en) | Anthraquinone derivative exerting lipase activating effect and antiobesity drug, food preparation and cosmetic comprising the same | |
| EP1371368A1 (en) | Salvianolic acid components as lipase inhibitors | |
| Lin et al. | Aqueous extract of Solanum nigrum attenuates Angiotensin-II induced cardiac hypertrophy and improves cardiac function by repressing protein kinase C-ζ to restore HSF2 deSUMOlyation and Mel-18-IGF-IIR signaling suppression | |
| JPH09278662A (en) | Antiallergic agent | |
| KR101792875B1 (en) | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease | |
| CN109007838A (en) | A kind of functional health care food and preparation method thereof of lecithin norcholesterol | |
| KR20200145054A (en) | Composition comprising radish extracts for preventing, improving and treating cardiovascular disease | |
| JP2008074735A (en) | Composition having inhibitory action on lipase and fat absorption inhibitor comprising the same as active ingredient | |
| US20190290715A1 (en) | Açai berry seed extract, fractions of açai berry seed extracts, process for obtaining açai berry seed extracts, pharmaceutical and food compositions and method for the treatment of diseases or disorders with açai berry seed extract | |
| Hirst et al. | Physiological and Pathological Considerations for the Use of Flaxseed as a Therapeutic Dietary Strategy | |
| US8993551B2 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
| JP5548379B2 (en) | Antihistamine containing pollen cargo | |
| KR101189865B1 (en) | Composition comprising the salted Alaska pollack roe or Alaska pollack roe for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases | |
| Abdullah et al. | Study of the effect of laurel plant (Laurus Nobilis) on some biochemical markers in diabetic mellitus rats | |
| US12029774B2 (en) | Açai berry seed extract, fractions of açai berry seed extracts, process for obtaining açai berry seed extracts, pharmaceutical and food compositions and method for the treatment of diseases or disorders with açai berry seed extract | |
| KR20230056234A (en) | A composition for improving metabolic syndrome-related diseases caused by endocrine disruptors comprising cirsium setidens extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181218 |
|
| WW01 | Invention patent application withdrawn after publication |